0001225208-17-002445.txt : 20170206
0001225208-17-002445.hdr.sgml : 20170206
20170206153514
ACCESSION NUMBER: 0001225208-17-002445
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170203
FILED AS OF DATE: 20170206
DATE AS OF CHANGE: 20170206
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Merck & Co., Inc.
CENTRAL INDEX KEY: 0000310158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 221918501
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
BUSINESS PHONE: 908-740-4000
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
FORMER COMPANY:
FORMER CONFORMED NAME: Merck & Co. Inc.
DATE OF NAME CHANGE: 20091103
FORMER COMPANY:
FORMER CONFORMED NAME: SCHERING PLOUGH CORP
DATE OF NAME CHANGE: 19920703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Holston Michael J
CENTRAL INDEX KEY: 0001390613
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-06571
FILM NUMBER: 17575481
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
4
1
doc4.xml
X0306
4
2017-02-03
0000310158
Merck & Co., Inc.
MRK
0001390613
Holston Michael J
MERCK & CO., INC.
2000 GALLOPING HILL ROAD
KENILWORTH
NJ
07033
1
EVP, General Counsel
Common Stock
2017-02-03
4
M
0
41279.0000
59.8600
A
105559.2270
D
Common Stock
2017-02-03
4
M
0
36680.0000
58.2200
A
142239.2270
D
Common Stock
2017-02-03
4
S
0
14000.0000
63.6904
D
128239.2270
D
Common Stock
2017-02-03
4
S
0
77959.0000
64.0027
D
50280.2270
D
Stock Option (right to buy)
59.8600
2017-02-03
4
M
0
41279.0000
0.0000
D
2016-05-01
2025-04-30
Common Stock
41279.0000
82560.0000
D
Stock Option (right to buy)
58.2200
2017-02-03
4
M
0
36680.0000
0.0000
D
2015-05-09
2024-05-08
Common Stock
36680.0000
18341.0000
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.5100 to $63.8900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.0000 to $64.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Holdings include shares acquired in dividend reinvestment transactions.
The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.
The option became exercisable in equal installments on 5/9/2015, 5/9/2016 and 5/9/2017.
Katie Fedosz as Attorney-in-Fact for Michael J. Holston
2017-02-06